Finance

Lists
Why is MDMA up 2,38%?
Dive Deeper
MDMA:CNSX
Pharmala Biotech Holdings Inc
CAD 0,22
+2,38%
(+0,0050) 1D
9 Okt., 16:00:00 GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for MDMA...
Open
CAD 0,21
High
CAD 0,22
Low
CAD 0,20
Mkt. cap
23,35 m
Avg. vol.
170,21 k
Volume
51,30 k
52-wk high
CAD 0,33
52-wk low
CAD 0,08
EPS
-CAD 0,02
No. of employees
3
Open
CAD 0,21
High
CAD 0,22
Low
CAD 0,20
Mkt. cap
23,35 m
Avg. vol.
170,21 k
Volume
51,30 k
52-wk high
CAD 0,33
52-wk low
CAD 0,08
EPS
-CAD 0,02
No. of employees
3
News stories
From web sources and news partners
About Pharmala Biotech Holdings Inc
CEO-
Employees3
Founded2021
HeadquartersToronto, Ontario, Kanada
Sector-
Last report
29 Jul. 2026
Fiscal period
Q3 2026
- / -
Revenue / Est. (CAD)
513,23 k / -
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in CAD
Aug. 2025
Nov. 2025
Feb. 2026
Mei 2026
Revenue
267,38 k
206,44 k
280,58 k
513,23 k
Cost of goods sold
34,04 k
34,84 k
22,41 k
174,69 k
Cost of revenue
34,04 k
34,84 k
22,41 k
174,69 k
Research and development expenses
44,91 k
41,10 k
40,53 k
44,91 k
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
404,68 k
320,96 k
367,29 k
472,32 k
Operating expense
553,47 k
498,41 k
559,82 k
810,59 k
Total operating expenses
587,50 k
533,25 k
582,22 k
985,28 k
Operating income
-320,13 k
-326,81 k
-301,64 k
-472,05 k
Other non operating income
-41,00 k
-16,84 k
-46,18 k
-40,97 k
EBT including unusual items
-361,13 k
-409,70 k
-337,70 k
-499,76 k
EBT excluding unusual items
-361,13 k
-343,65 k
-347,82 k
-513,01 k
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-361,13 k
-409,70 k
-337,70 k
-499,76 k
Net profit margin
-135,07%
-198,46%
-120,35%
-97,37%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
29,19 k
29,76 k
29,74 k
30,02 k
EBITDA
-306,98 k
-313,10 k
-287,95 k
-458,08 k
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme